Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides.

Human apolipoprotein-B mRNA-editing catalytic polypeptide-like 3G (A3G) is a cytidine deaminase that restricts retroviruses, endogenous retro-elements and DNA viruses. A3G plays a key role in the anti-HIV-1 innate cellular immunity. The HIV-1 Vif protein counteracts A3G mainly by leading A3G towards the proteosomal machinery and by direct inhibition of its enzymatic activity. Both activities involve direct interaction between Vif and A3G. Disrupting the interaction between A3G and Vif may rescue A3G antiviral activity and inhibit HIV-1 propagation. Here, mapping the interaction sites between A3G and Vif by peptide array screening revealed distinct regions in Vif important for A3G binding, including the N-terminal domain (NTD), C-terminal domain (CTD) and residues 83-99. The Vif-binding sites in A3G included 12 different peptides that showed strong binding to either full-length Vif, Vif CTD or both. Sequence similarity was found between Vif-binding peptides from the A3G CTD and NTD. A3G peptides were synthesized and tested for their ability to counteract Vif action. A3G 211-225 inhibited HIV-1 replication in cell culture and impaired Vif dependent A3G degradation. In vivo co-localization of full-length Vif with A3G 211-225 was demonstrated by use of FRET. This peptide has the potential to serve as an anti-HIV-1 lead compound. Our results suggest a complex interaction between Vif and A3G that is mediated by discontinuous binding regions with different affinities.

[1]  B. Schnierle,et al.  HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G. , 2005, Current HIV research.

[2]  M. Malim,et al.  Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation , 2007, Journal of Virology.

[3]  S. Rüdiger,et al.  Studying protein-protein interactions using peptide arrays. , 2011, Chemical Society reviews.

[4]  B. Cullen,et al.  A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Wolf Reik,et al.  Mice Deficient in APOBEC2 and APOBEC3 , 2005, Molecular and Cellular Biology.

[6]  Jared R. Auclair,et al.  Mass spectrometry analysis of HIV‐1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity , 2007, Proteins.

[7]  M. Malim,et al.  RNA-Dependent Oligomerization of APOBEC3G Is Required for Restriction of HIV-1 , 2009, PLoS pathogens.

[8]  Sylvie Rato,et al.  HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. , 2007, Molecular immunology.

[9]  S. Ikeda,et al.  MDM2 is a novel E3 ligase for HIV-1 Vif , 2009, Retrovirology.

[10]  B. Spire,et al.  Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor , 1997, Journal of virology.

[11]  H. Matsuo,et al.  An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. , 2009, Journal of molecular biology.

[12]  V. Pathak,et al.  Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F , 2007, Journal of Virology.

[13]  Hui Zhang,et al.  Human Immunodeficiency Virus Type 1 Vif Protein Is an Integral Component of an mRNP Complex of Viral RNA and Could Be Involved in the Viral RNA Folding and Packaging Process , 2000, Journal of Virology.

[14]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[15]  H. Benyamini,et al.  The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. , 2009, Protein engineering, design & selection : PEDS.

[16]  H. Matsuo,et al.  Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G , 2008, Nature.

[17]  T. Rana,et al.  Analysis of HIV-1 Viral Infectivity Factor-mediated Proteasome-dependent Depletion of APOBEC3G , 2005, Journal of Biological Chemistry.

[18]  J. Goncalves,et al.  Phosphorylation of Vif and Its Role in HIV-1 Replication (*) , 1996, The Journal of Biological Chemistry.

[19]  S. Bernacchi,et al.  HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation , 2009, Nucleic acids research.

[20]  M. Llano,et al.  Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. , 2004, Virology.

[21]  Xiaojun Wang,et al.  Identification of a Novel WxSLVK Motif in the N Terminus of Human Immunodeficiency Virus and Simian Immunodeficiency Virus Vif That Is Critical for APOBEC3G and APOBEC3F Neutralization , 2009, Journal of Virology.

[22]  Reuben S Harris,et al.  The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G , 2003, Current Biology.

[23]  Xiao-Fang Yu,et al.  A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G , 2009, Journal of Virology.

[24]  M. Khan,et al.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. , 2003 .

[25]  A. Telenti,et al.  Model Structure of Human APOBEC3G , 2007, PloS one.

[26]  Keyang Chen,et al.  Virion-associated Uracil DNA Glycosylase-2 and Apurinic/Apyrimidinic Endonuclease Are Involved in the Degradation of APOBEC3G-edited Nascent HIV-1 DNA* , 2007, Journal of Biological Chemistry.

[27]  W. Greene,et al.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. , 2003, Molecules and Cells.

[28]  V. Pathak,et al.  A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Gerhard Wagner,et al.  A solubility-enhancement tag (SET) for NMR studies of poorly behaving proteins , 2001, Journal of biomolecular NMR.

[30]  Xiaojun Wang,et al.  Identification of a Critical T(Q/D/E)x5ADx2(I/L) Motif from Primate Lentivirus Vif Proteins That Regulate APOBEC3G and APOBEC3F Neutralizing Activity , 2010, Journal of Virology.

[31]  A. Friedler,et al.  Human immunodeficiency virus type 1 Vif‐derived peptides inhibit the viral protease and arrest virus production , 1998, FEBS letters.

[32]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[33]  S. Bernacchi,et al.  Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors , 2009, Microbiology and Molecular Biology Reviews.

[34]  W. Greene,et al.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. , 2010, Molecular aspects of medicine.

[35]  Reuben S. Harris,et al.  Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.

[36]  D. Trono,et al.  A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action* , 2004, Journal of Biological Chemistry.

[37]  C. K. Grant,et al.  The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells , 1997, Journal of virology.

[38]  M. Marin,et al.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation , 2003, Nature Medicine.

[39]  J. Goncalves,et al.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. , 2004, Genes & development.

[40]  W. Blair,et al.  High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target , 2005, Antimicrobial Agents and Chemotherapy.

[41]  A. Friedler,et al.  Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. , 2002, The Journal of general virology.

[42]  A. Gronenborn,et al.  HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain , 2009, Proceedings of the National Academy of Sciences.

[43]  G. Manning,et al.  Mutational Alteration of Human Immunodeficiency Virus Type 1 Vif Allows for Functional Interaction with Nonhuman Primate APOBEC3G , 2006, Journal of Virology.

[44]  N. Landau,et al.  A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Wedekind,et al.  Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. , 2003, Trends in genetics : TIG.

[46]  M. Khan,et al.  HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. , 2008, Virology.

[47]  A. Friedler,et al.  Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors. , 1999, Journal of molecular biology.

[48]  Jian-Dong Jiang,et al.  Small Molecular Compounds Inhibit HIV-1 Replication through Specifically Stabilizing APOBEC3G* , 2010, The Journal of Biological Chemistry.

[49]  HaroldC. Smith,et al.  Retrovirology Open Access the Dimerization Domain of Hiv-1 Viral Infectivity Factor Vif Is Required to Block Virion Incorporation of Apobec3g , 2007 .

[50]  M. Emerman,et al.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.

[51]  Richard T D'Aquila,et al.  The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. , 2008, Virology.

[52]  C. Tisné,et al.  Advances in the structural understanding of Vif proteins. , 2008, Current HIV research.

[53]  E. Thomas,et al.  A Zinc-binding Region in Vif Binds Cul5 and Determines Cullin Selection* , 2006, Journal of Biological Chemistry.

[54]  Hui Zhang,et al.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.

[55]  J. Wedekind,et al.  The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Y. Xiong,et al.  Characterization of a novel Cullin5 binding domain in HIV-1 Vif. , 2007, Journal of molecular biology.

[57]  Gersende Caron,et al.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.

[58]  Brent R. Martin,et al.  Mammalian cell–based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity , 2005, Nature Biotechnology.

[59]  M. Malim,et al.  Rationalisation of the Differences between APOBEC3G Structures from Crystallography and NMR Studies by Molecular Dynamics Simulations , 2010, PloS one.

[60]  Erez Pery,et al.  Regulation of APOBEC3 Proteins by a Novel YXXL Motif in Human Immunodeficiency Virus Type 1 Vif and Simian Immunodeficiency Virus SIVagm Vif , 2008, Journal of Virology.

[61]  R. König,et al.  Complementary function of the two catalytic domains of APOBEC3G. , 2005, Virology.

[62]  C. Burrell,et al.  The role of Vif during HIV-1 infection: interaction with novel host cellular factors. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[63]  Mariana Santa-Marta,et al.  HIV-1 Vif Can Directly Inhibit Apolipoprotein B mRNA-editing Enzyme Catalytic Polypeptide-like 3G-mediated Cytidine Deamination by Using a Single Amino Acid Interaction and Without Protein Degradation* , 2005, Journal of Biological Chemistry.

[64]  B. Carlson,et al.  Association of Human Immunodeficiency Virus Type 1 Vif with RNA and Its Role in Reverse Transcription , 2000, Journal of Virology.

[65]  Xiaojiang S. Chen,et al.  The current structural and functional understanding of APOBEC deaminases , 2009, Cellular and Molecular Life Sciences.

[66]  Tomoki Yamashita,et al.  Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity. , 2010, Microbes and infection.

[67]  Y. Xiong,et al.  Structural Insight into the Human Immunodeficiency Virus Vif SOCS Box and Its Role in Human E3 Ubiquitin Ligase Assembly , 2008, Journal of Virology.

[68]  Mark R. Sanderson,et al.  The SOCS-Box of HIV-1 Vif Interacts with ElonginBC by Induced-Folding to Recruit Its Cul5-Containing Ubiquitin Ligase Complex , 2010, PLoS pathogens.

[69]  V. Uversky,et al.  Flexible Viruses: Structural Disorder in Viral Proteins , 2012 .

[70]  Hong Cao,et al.  Small-molecule inhibition of HIV-1 Vif , 2008, Nature Biotechnology.

[71]  B. Strack,et al.  Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.

[72]  R. W. Davis,et al.  Identification of 81LGxGxxIxW89 and 171EDRW174 Domains from Human Immunodeficiency Virus Type 1 Vif That Regulate APOBEC3G and APOBEC3F Neutralizing Activity , 2010, Journal of Virology.

[73]  Shu Zheng,et al.  Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Erez Pery,et al.  Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type 1 Vif and Inhibitors of Vif-APOBEC3G Binding , 2007, Journal of Virology.

[75]  Ryan C. Burdick,et al.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. , 2009, Trends in pharmacological sciences.

[76]  L. Kleiman,et al.  Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. , 2008, Virology.

[77]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..